AGN Stock Overview
A biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Argenica Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.72 |
| 52 Week High | AU$0.98 |
| 52 Week Low | AU$0.41 |
| Beta | 0.73 |
| 11 Month Change | -5.23% |
| 3 Month Change | -8.23% |
| 1 Year Change | 64.77% |
| 33 Year Change | 31.82% |
| 5 Year Change | n/a |
| Change since IPO | 178.85% |
Recent News & Updates
Recent updates
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans
Sep 23
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth
Jan 12Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business
Jul 20Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business
Apr 20We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate
Nov 30Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans
Aug 12Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation
Apr 29Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation
Dec 30We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate
Sep 16Shareholder Returns
| AGN | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -3.3% | -11.8% | 1.5% |
| 1Y | 64.8% | 39.8% | 17.2% |
Return vs Industry: AGN exceeded the Australian Pharmaceuticals industry which returned 39.8% over the past year.
Return vs Market: AGN exceeded the Australian Market which returned 17.2% over the past year.
Price Volatility
| AGN volatility | |
|---|---|
| AGN Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: AGN has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: AGN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Liz Dallimore | argenica.com.au |
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia.
Argenica Therapeutics Limited Fundamentals Summary
| AGN fundamental statistics | |
|---|---|
| Market cap | AU$89.66m |
| Earnings (TTM) | -AU$5.48m |
| Revenue (TTM) | AU$2.60m |
35.7x
P/S Ratio-16.9x
P/E RatioIs AGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGN income statement (TTM) | |
|---|---|
| Revenue | AU$2.60m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.60m |
| Other Expenses | AU$8.08m |
| Earnings | -AU$5.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.043 |
| Gross Margin | 100.00% |
| Net Profit Margin | -210.92% |
| Debt/Equity Ratio | 0% |
How did AGN perform over the long term?
See historical performance and comparison